`
`Patentee: Acheampong,ef al.
`
`Examiner: Marcela M Cordero Garcia
`
`PATENT
`
`Patent No.: 9,248,191
`
`Group Art Unit: 1676
`
`Issue Date: February 2, 2016
`
`Confirmation No. 9616
`
`For: METHODS OF PROVIDING
`THERAPEUTIC EFFECTS USING
`CYCLOSPORIN COMPONENTS
`
`Customer No.: 51957
`
`REQUEST FOR CERTIFICATE OF CORRECTION
`
`Attn: Certificate of Correction Branch
`Commissionerfor Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`It is requested that a Certificate of Correction be issued correcting printing errors appearing
`
`in the above-identified United States patent.
`
`Pursuant to 1.20(a), the examineris authorized to charge the Certificate of Correction fee
`
`of $100.00 or any additional fees or credit overpayment to Deposit Account No. 010885.
`
`Issuance of the Certificate of Correction would neither expand nor contract the scope of the
`
`claims as properly allowed, and re-examination is not required.
`
`Respectfully submitted,
`
`Date _February 16, 2016
`
`By: /Laura L. Wine/
`Laura L. Wine
`Reg. No.: 68681
`
`TEVA - EXHIBIT 1004 (PART 1 OF 5)
`
`0001
`
`0001
`
`TEVA - EXHIBIT 1004 (PART 1 OF 5)
`
`
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Patentee: Acheampong,ef al.
`
`Examiner: Marcela M Cordero Garcia
`
`Patent No.: 9,248,191
`
`Group Art Unit: 1676
`
`Issue Date: February 2, 2016
`
`Confirmation No. 9616
`
`For: METHODS OF PROVIDING
`THERAPEUTIC EFFECTS USING
`CYCLOSPORIN COMPONENTS
`
`Customer No.: 51957
`
`Attn: Certificate of Correction Branch
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Weare transmitting herewith the attached:
`
`X Request for Certificate of Correction.
`X Certificate of Correction Form - PTO-1050
`
`Please charge any additional fees or credit overpayment to Deposit Account No. 010885.
`
`Respectfully submitted,
`
`
`
`/LauraL.Wine/
`
`Date: February 16, 2016
`
`By Laura L. Wine
`Reg. No.:68681
`
`0002
`
`0002
`
`
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`Page 1 of 4
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`insert - - Re-Examination - -.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`On the first page, in field (63), in column 1,
`
`in “Related U.S. Application Data”, line 4,
`
`delete “and” and insert - - which is - -, therefor.
`
`On the Page 2, in column 2, under “Other Publications”, line 9, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 1, under “Other Publications”, line 52, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 1, under “Other Publications”, line 61, delete “Muscosal”
`
`and insert - - Mucosal - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 24, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 28, delete
`
`“Polyocyethylene” and insert - - Polyoxyethylene - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 29, delete
`
`“PhysicoChemical” and insert - - Physico-Chemical - -, therefor.
`
`On the Page 3, in column 2, under “Other Publications”, line 39, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 13, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 35, delete “a” and
`
`insert - - A - -, therefor.
`
`On the Page 4, in column 1, under “Other Publications”, line 48, after “U.S.”
`
`0003
`
`0003
`
`
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 2 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`In column 1, line 53, delete “al.” and insert - - al, - -, therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`On the Page 4, in column 2, under “Other Publications”, line 10, delete “Allegran,”
`
`and insert - - Allergan, - -, therefor.
`
`On the Page 4, in column 2, under “Other Publications”, line 43, delete “Occular” and
`
`insert - - Ocular - -, therefor.
`
`On the Page 5, in column 1, under “Other Publications”, line 58, after “Systane”
`
`insert - - Products, Systane - -.
`
`On the Page 5, in column 1, under “Other Publications”, line 59, delete “http;//” and
`
`insert - - http:// - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 22, delete “Waston” and
`
`insert - - Watson - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 31, delete “No.” and
`
`insert - - Nos. - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 33,
`
`delete “5050)(2)(13)” and insert - - 505(j)(2)(B) - -, therefor.
`
`On the Page 5, in column 2, under “Other Publications”, line 48,
`
`delete “5050)(2)(13)” and insert - - 505(j)(2)(B) - -, therefor.
`
`In column 1, line 8, delete “13/961.828”"and insert - - 13/961,828 - -, therefor.
`
`In column 1, line 36, delete “a” and insert - - A - -, therefor.
`
`In column 1, line 37, delete “a” and insert - - A - -, therefor.
`
`In column 1, line 39, delete “2002,” and insert - - 2002 - -, therefor.
`
`0004
`
`0004
`
`
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 3 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`insert - - 2-methacryloyloxyethylsulfonic - -, therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`In column 2, line 65, delete “kerapoconjunctivitis,” and
`
`insert - - keratoconjunctivitis, - -, therefor.
`
`In column 3, line 12, delete “clyclcosporin” and insert - - cyclosporin - -, therefor.
`
`In column 3, line 52, delete “were” and insert - - are - -, therefor.
`
`In column 4, line 23, After “more” insert - - of - -.
`
`In column 5, line 9, delete “kerapoconjunctivitis,” and
`
`insert - - keratoconjunctivitis, - -, therefor.
`
`In column 5, line 66, After “with” delete “a”.
`
`In column 6, line 3, delete “acetronitrile-based” and insert - - acetonitrile-based - -,
`
`therefor.
`
`In column 9, line 20, delete “each” and insert - - such - -, therefor.
`
`In column 9, line 48, delete “extant” and insert - - extent - -, therefor.
`
`In column 9, line 60, delete “benefiting” and insert - - benefitting - -, therefor.
`
`In column 10, line 22, delete “informing” and insert - - in forming - -, therefor.
`
`In column 10, line 35, delete “amphorteric” and insert - - amphoteric - -, therefor.
`
`In column 11, line 7, delete “methylhydroxyethlystarches” and
`
`insert - - methylhydroxyethylstarches - -, therefor.
`
`In column 11, line 10, delete “glucoaminoglycans” and
`
`insert - - glycosaminoglycans - -, therefor.
`
`In column 11, line 28, delete “2-methacrylolyoxyethlysulfonic” and
`
`0005
`
`0005
`
`
`
`UNITED STATES PATENT AND TRADEMARKOFFICE
`CERTIFICATE OF CORRECTION
`
`PATENT NO
`
`19,248,191
`
`DATED
`
`: February 2, 2016
`
`INVENTOR(S)
`
`: Andrew Acheampongetal.
`
`Page 4 of 4
`
`PTO/SB/44 (09-07)
`Approved for use through 08/31/2013. OMB 0651-0033
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Underthe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit displays a valid OMB control number.
`(Also Form PTO-1050)
`
`therefor.
`
`It is certified that errors appear in the above-identified patent and that said Letters Patentis
`
`hereby corrected as shown below:
`
`In column 11, line 29, delete “2-methacryloyloxethylsulfonates” and
`
`insert - - 2-methacryloyloxyethylsulfonates - -, therefor.
`
`In column 11, line 30, delete “2-hydroxyproplysulfonic” and
`
`insert - - 2-hydroxypropylsulfonic - -, therefor.
`
`In column 11, line 45, delete “crosslinked” and insert - - cross-linked - -, therefor.
`
`In column 12, line 9, delete “polyvinyl,” and insert - - polyvinyl - -, therefor.
`
`In column 13, line 1, delete “Disoxide,” and insert - - Dioxide, - -, therefor.
`
`In column 13, line 34, delete “materiel” and insert - - material - -, therefor.
`
`In column 14, line 32, delete “Premulen ®” and insert - - Pemulen® - -, therefor.
`
`In column 15, line 24, in Claim 1, delete “005%” and insert - - 0.05%- -, therefor.
`
`In column 15, line 61, in Claim 11, delete “claim 2,” and insert - - claim 6, - -,
`
`0006
`
`0006
`
`
`
`Electronic Patent Application Fee Transmittal
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`femn
`
`
`
`Filing Fees for Utility under 35 USC 111(a)
`
`Description
`
`Fee Code
`
`Quantity
`
`Sub-Total in
`
`USD(S)
`
`Basic Filing:
`
`Miscellaneous-Filing:
`
`Patent-Appeals-and-Interference:
`
`Post-Allowance-and-Post-Issuance:
`
`0007
`
`0007
`
`
`
`Extension-of-Time:
`
`Total in USD ($)
`
`Miscellaneous:
`
`0008
`
`0008
`
`
`
`Title of Invention:
`
`METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN
`COMPONENTS
`
`Electronic AcknowledgementReceipt
`
`Application Number:
`
`14222478
`
`International Application Number:
`
`Confirmation Number:
`
`9616
`
`
`
`eC
`
`Paymentinformation:
`
`Charge any Additional Fees required under 37 CFR 1.17 (Patent application and reexamination processing fees)
`
`Deposit Account
`
`Authorized User
`
`010885
`
`WINE, LAURAL.
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpaymentas follows:
`
`Charge any Additional Fees required under 37 CFR 1.16 (National application filing, search, and examination fees)
`
`0009
`
`0009
`
`
`
`Charge any Additional Fees required under 37 CFR 1.19 (Document supplyfees)
`
`Charge any Additional Fees required under 37 CFR 1.20 (Post Issuance fees)
`
`Charge any Additional Fees required under 37 CFR 1.21 (Miscellaneous fees and charges)
`
`File Listing:
`
`Pages
`Multi
`File Size(Bytes)/
`DocumentDescription
`Document
`
`
`
`Number Message Digest|Part/.zip|P (if appl.)
`164544
`
`Requestfor Certificate of Correction
`
`COCAllergan1 7618CON6CON1
`AP9248191 pdf
`
`896d 1a453cf219586794f8fadeSfefd8b525q
`808
`
`the application.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105)will be issued in due course, subject to prescriptions concerning
`national security, and the date shownon this AcknowledgementReceiptwill establish the international filing date of
`
`Information:
`
`Information:
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`77d8f5cf7d4c6377"431 bSacaSd39b369a69
`oofs
`
`This AcknowledgementReceipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable.It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary componentsfora filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shownonthis
`AcknowledgementReceiptwill establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903indicating acceptanceof the application as a
`national stage submission under35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`0010
`
`0010
`
`
`
`
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Vatent and TrademarkOffice
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`www.uspto.g:
`Alexandria, Virginia 22313-1450
`
`APPLICATION NO.
`
`14/222,478
`
`ISSUE DATE
`
`02/02/2016
`
`51957
`
`7590
`
`01/13/2016
`
`ALLERGAN,INC.
`2525 DUPONT DRIVE,T2-7H
`IRVINE, CA 92612-1599
`
`PATENT NO.
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`9248191
`
`17618CON6CON1 (AP)
`
`9616
`
`The projected patent numberandissue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include
`an indication of the adjustmenton the front page.
`
`If a Continued Prosecution Application (CPA) wasfiled in the above-identified application, the filing date that
`determines Patent Term Adjustmentis the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEBsite (http://pair-uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management
`(ODM)at (571)-272-4200.
`
`APPLICANT(s)(Please see PAIR WEBsite http://pair.uspto.gov for additional applicants):
`
`Allergan, Inc., Irvine, CA;
`Andrew Acheampong,Irvine, CA;
`Diane D. Tang-Liu, Las Vegas, CA;
`James N. Chang, Newport Beach, CA;
`David F. Power, San Clemente, CA;
`
`The United States represents the largest, most dynamic marketplace in the world andis an unparalleled location
`for business investment, innovation, and commercialization of new technologies. The USA offers tremendous
`resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation
`worksto encourage andfacilitate business investment. To learn more about why the USAis the best country in
`the world to develop technology, manufacture products, and grow your business, visit SelectUSA. gov.
`
`IR103 (Rev. 10/09)
`
`0011
`
`0011
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`51957
`
`7590
`
`12/18/2015
`
`ALLERGAN, INC.
`2525 DUPONT DRIVE,T2-7H
`IRVINE, CA 92612-1599
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`DATE MAILED: 12/18/2015
`
`17618CON6CONI1 (AP)
`Andrew Acheampong
`03/21/2014
`14/222,478
`TITLE OF INVENTION: METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`9616
`
`
`
`
`
`
`
`
`
`
`
`APPLN. TYPE PUBLICATION FEE DUE|PREV. PAID ISSUE FEEENTITY STATUS ISSUE FEE DUE TOTAL FEE(S) DUE DATE DUE
`
`
`
`
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`03/18/2016
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCEIS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED.
`SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLYTO THIS NOTICE:
`
`I. Review the ENTITY STATUSshownabove.If the ENTITY STATUSis shown as SMALL or MICRO,verify whether entitlement to that
`entity status still applies.
`If the ENTITY STATUSis the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`If the ENTITY STATUSis changed from that shown above, on PART B - FEE(S) TRANSMITTAL,complete section number5 titled
`"Change in Entity Status (from status indicated above)".
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amountof small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL,orits equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE(if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B isfiled, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalentof Part B.
`
`IH. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advisedto the contrary.
`
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenancefees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 02/11)
`
`Page | of 3
`
`0012
`
`0012
`
`
`
`PART B - FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`
`through 5 should be completed where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE(if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS"for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS(Note: Use Block 1 for any changeof address)
`
`can only be used for domestic mailings of the
`Note: A certificate of mailing
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`apers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`12/18/2015
`7590
`51957
`States Postal Service with sufficient
`postage for first class mail in an envelope
`ALLERGAN, INC.
`
`: ddressedtothe Mail "EEE address. ab being. facsimil
`
`
`
`
`
`
`addressed
`to
`the Mail Stop ISSUE FEE address above, or
`being
`facsimile
`2525 DUPONT DRIVE, T2-7H
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`IRVINE, CA 92612-1599
`(Depositor's name)
`(Signature)
`
`(ate)
`
`APPLICATION NO.
`
`FILING DATE
`
`
`
`
`
` FIRST NAMED INVENTOR
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`17618CON6CON1 (AP)
`Andrew Acheampong
`03/21/2014
`14/222,478
`TITLE OF INVENTION: METHODS OF PROVIDING THERAPEUTIC EFFECTS USING CYCLOSPORIN COMPONENTS
`
`9616
`
`
`
`
`
`
`
`APPLN. TYPE PUBLICATION FEE DUE|PREV. PAID ISSUE FEEENTITY STATUS ISSUE FEE DUE TOTAL FEE(S) DUE DATE DUE
`
`
`
`
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`03/18/2016
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`514-020500
`
`2. For printing on the patent front page,list
`(1) The namesofup to 3 registered patent attorneys
`or agents OR,alternatively,
`(2) The nameofa single firm (having as a member a
`2
`registered attorney or agent) and the namesof up to
`2 registered patent attorneys or agents. If nonameis
`listed, no namewill be printed.
`
`
`
`43
`
`
`
`
`
`1. Change of correspondence address or indication of "Fee Address" (37
`CFR 1.363).
`LI Change of correspondence address (or Change of Correspondence
`Address form PTO/SB/122) attached.
`LI "Fee Address" indication (or "Fee Address” Indication form
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`Numberis required.
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT(printor type)
`If an assignee is identified below, the document has been filed for
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent.
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAMEOF ASSIGNEE
`(B) RESIDENCE:(CITY and STATE OR COUNTRY)
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) :
`
`LV individual LJ Corporation or other private group entity (J Government
`
`4a. The following fee(s) are submitted:
`L] Issue Fee
`_] Publication Fee (No small entity discount permitted)
`LT Advance Order - # of Copies
`
`
`
`4b. Paymentof Fee(s): (Please first reapply any previously paid issue fee shown above)
`LIA checkis enclosed.
`Lj Paymentby credit card. Form PTO-2038 is attached.
`[I The directoris hereby authorized to charge the required fee(s), any deficiency, or credits any
`overpayment, to Deposit Account Number
`(enclose an extra copy ofthis form).
`
`
`
`5. Change in Entity Status (from status indicated above)
`| Applicantcertifying micro entity status. See 37 CFR 1.29
`
` Lj Applicant changing to regular undiscounted fee status.
`
`Lj Applicant asserting small entity status. See 37 CFR 1.27
`
`
`NOTE:Absenta valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue
`fee paymentin the micro entity amountwill not be accepted at the risk of application abandonment.
`
`NOTE:If the application was previously under micro entity status, checking this box will be taken
`to be a notification ofloss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification ofloss of entitlement to small or micro
`entity status, as applicable.
`
`NOTE: This form mustbe signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 14 for signature requirements and certifications.
`
`Authorized Signature
`
`Typed or printed name
`
`
`Date
`
`Registration No.
`
`PTOL-85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB0651-0033
`
`USS. Patent and Trademark Office; U.S. DEPARTMENT OF COOMBSCE
`
`Page 2 of 3
`
`0013
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`APPLICATION NO.
`
`FILING DATE
`
`
`
`
`FIRST NAMED INVENTOR
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`ATTORNEY DOCKETNO.
`
`CONFIRMATION NO.
`
`14/222,478
`
`03/21/2014
`
`Andrew Acheampong
`
`17618CON6CONI1 (AP)
`
`9616
`
`51957
`
`7590
`
`12/18/2015
`
`ALLERGAN, INC.
`2525 DUPONT DRIVE, T2-7H
`IRVINE, CA 92612-1559
`
`CORDERO GARCIA, MARCELA M
`
`1676
`
`DATE MAILED: 12/18/2015
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(Applicationsfiled on or after May 29, 2000)
`
`The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.
`
`to eliminate the
`Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i)
`requirement that the Office provide a patent term adjustment determination with the notice of allowance. See
`Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer
`providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to
`provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant
`approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the
`patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term
`adjustment) should follow the process outlined in 37 CFR 1.705.
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of
`Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be
`directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.
`
`PTOL-85 (Rev. 02/11)
`
`Page 3 of 3
`
`0014
`
`0014
`
`
`
`OMB Clearance and PRA Burden Statement for PTOL-85 Part B
`
`The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and
`Budget approval before requesting most types of information from the public. When OMB approves an agency
`request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration
`date for the agency to display on the instrument that will be used to collect the information and (ii) requires the
`agency to inform the public about the OMB Control Number’s legal significance in accordance with 5 CFR
`1320.5(b).
`
`The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain
`or retain a benefit by the public whichis to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary
`depending upon the individual case. Any comments on the amount of time you require to complete this form
`and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT
`SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box
`1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to
`respondto a collection of information unlessit displays a valid OMB control number.
`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant
`to the
`requirements of the Act, please be advised that: (1) the general authority for the collection of this informationis
`35 U.S.C. 2(b)(2); (2) furnishing of the informationsolicited is voluntary; and (3) the principal purpose for which
`the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission
`related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and
`Trademark Office may not be able to process and/or examine your submission, which mayresult in termination of
`proceedings or abandonmentof the application or expiration of the patent.
`
`The information provided by youin this form will be subject to the following routine uses:
`1. The information on this form will be treated confidentially to the extent allowed under the Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records
`may be disclosed to the Department of Justice to determine whether disclosure of these records is required
`by the Freedom of Information Act.
`2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance
`from the Memberwith respect to the subject matter of the record.
`4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having
`need for the information in order to perform a contract. Recipients of information shall be required to
`comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's
`responsibility to recommend improvements in records managementpractices and programs, under authority
`of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations
`governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive.
`Such disclosure shall not be used to make determinations about individuals.
`8. A record from this system of records may be disclosed, as a routine use, to the public after either publication
`of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the
`record was filed in an application which became abandoned or in which the proceedings were terminated
`and which application is referenced by either a published application, an application open to public
`inspection or an issued patent.
`9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency,if the USPTO becomesawareof a violation or potential violation of law or regulation.
`
`0015
`
`0015
`
`
`
`
`
`Applicant-Initiated Interview Summary
`
`
` 14/222,478 ACHEAMPONG ETAL.
`Examiner
`Art Unit
`
`Application No.
`
`Applicant(s)
`
`MARCELAM. CORDERO
`GARCIA
`
`1676
`
`All participants (applicant, applicant’s representative, PTO personnel):
`
`(1) MARCELA M. CORDERO GARCIA.
`
`(2) LAURA L.WINE.
`
`Date of Interview: 77 December 2015.
`
`(3)
`
`(4)
`
`,
`
`,
`
`Type:
`
`[(] Video Conference
`[&X] Telephonic
`[-] Personal[copy given to: [J applicant
`
`[J] applicant’s representative]
`
`Exhibit shown or demonstration conducted:
`If Yes, brief description:
`
`[] Yes
`
`X] No.
`
`[101 [112 [102 (103 [kjOthers
`Issues Discussed
`(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)
`
`Claim(s) discussed: All, in general.
`
`Identification of prior art discussed: US 9,101,574.
`
`Substance of Interview
`(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include:identification or clarification of a
`reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied referencesetc...)
`
`See Continuation Sheet.
`
`
`
`Applicant recordation instructions: The formal written reply to the last Office action must include the substance of the interview. (See MPEP
`section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or
`thirty days from this interview date, or the mailing date of this interview summaryform, whichever islater, to file a statement of the substance of the
`interview
`
`Examinerrecordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of
`the substance of an interview should includethe items listed in MPEP 713.04 for complete and proper recordation including the identification of the
`general thrust of each argumentor issue discussed, a general indication of any other pertinent matters dis